Azaindole compounds as histone methyltransferase inhibitors

A compound of Formula (I):

• wherein:
• X is CR1;
• Y is CR2;
• Q is N and P, T, and U are independently CH or C (when R4 or R5 is attached);
• Z is NR6, wherein R6 is hydrogen, alkyl, or cycloalkyl;
• one of R1 and R2 is hydrogen and the other is selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cycloalkyl;
• R3 is —W-alkylene-R7, wherein:
• —W-alkylene- is —O—(CH2)1-3* or —O—(CH2)2—O—(CH2)2—*, wherein * indicates the point of attachment to R7;
• R7 is —NRaNRb, wherein Ra and Rb are alkyl;
• or Ra and Rb together with the nitrogen to which they are attached form pyrrolidinyl, wherein said pyrrolidinyl is optionally substituted with one or two substituents independently selected from alkyl, halo, haloalkyl, hydroxy, alkoxy, and haloalkoxy;
• R4 and R5 are independently alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halo, hydroxy, haloalkoxy, alkoxy, cyano, NH2, NRcRd, alkoxyalkylamino, hydroxyalkylamino, aminoalkylamino, hydroxyalkyl, alkoxyalkyl, alkylthio, alkoxyalkyloxy, or phenyl, wherein the phenyl or the cycloalkyl, either alone or as part of another group are optionally substituted with one, two, or three substituents independently selected from alkyl, halo, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, alkoxy, NH2, alkylamino, dialkylamino, carboxy, carboxyalkyl, and alkoxycarbonyl, and wherein the alkyl of R4 and R5 is optionally substituted with cycloalkyl, and the alkenyl and the alkynyl of R4 and R5 are independently optionally substituted with hydroxy or cycloalkyl;
• Rc is hydrogen, alkyl, or cycloalkyl;
• Rd is alkyl or cycloalkyl;
• and
• v and w are independently 0 or 1;
• or a pharmaceutically acceptable salt thereof.